INTRODUCTION
In the war on cancer, "oneself " is our normal tissues, to which many fields of study are devoted. Normal tissues can be understood by their cell biology, physiology, development, biochemistry, etc., and there is substantial consensus on how the mechanisms should be dissected. The enemy, of course, is cancer cells, which evolve continually driven by mutation and natural selection (20, 102) . This process of evolutionary change drives increased proliferation of tumors. Therefore, tumorigenesis needs to be approached as an evolutionary phenomenon.
In this war, we not only do not understand the enemy well but do not even appear to agree on how best to understand the evolution of the enemy. In the past two decades, cancer biology studies have developed a system of interpreting cancer evolution (3, 18, 49, 92, 101, 110, 125, 126, 136, 139, 149) . However, this interpretation is often at odds with the principles of molecular evolutionary biology developed in the past 50 years by studying natural populations (23, 30, 38, 59, 70, 79, 96, 99, 144) . This review aims at bridging evolutionary biology and cancer biology.
To reconcile the divergent approaches to tumorigenesis, we reinterpret the data that have been extensively analyzed in previous reports (12, 27, 51, 68, 77, 105, 128, 136) . On the basis of those analyses, well-established theories of molecular population genetics are introduced (30, 33, 38, 59, 70, 140) . Therefore, although the presentation in this review may at times be different from the published literature, it is a matter of divergent interpretations of the same set of observations.
A central issue for such a review is whether the theories developed to study natural populations are suited to cell populations. In the section below, we discuss the differences between the two processes in relation to the merits and limitations of these theories.
CANCER EVOLUTION VERSUS ORGANISMAL EVOLUTION
Tumorigenesis has increasingly been accepted as an evolutionary process and populations of cancerous cells evolve, much like populations of organisms do. However, not all evolutionary principles are universally applicable, and cancer indeed follows distinct evolutionary paths that are unusual in many respects.
First, tumorigenesis is a process with extremely small divergence in DNA sequences (Figure 1 ). The observations are based on many short branches, whereas the evolutionary data in natural populations consist of a single long branch (human to macaque, for example). This short evolutionary distance is the defining feature of cancer evolution. Evolutionary studies are often categorized by the level of divergence (d; the number of nucleotide substitutions per site) of the taxa of interest (see Figure 1 ). Large-scale divergence, such as that between mammalian orders, is the realm of macroevolutionary biology, where d is generally much larger than 10 −1 . Microevolutionary biology focuses on the incipient phase of divergence between individuals of the same species or between closely related species, with d roughly in the range of 10 −3 to 10 −1 . For example, between human and chimpanzee, d ∼ 0.012 and the difference between two humans is approximately 0.07% (28) . Divergence of less than 10 −4 usually provides little evolutionary information. Cancer evolution, in 
Figure 1
The scales of organismal evolution and cancer evolution. The evolutionary distance (d; number of differences per nucleotide) between organisms is usually >0.1 in macroevolution and between 10 −3 and 10 −1 in microevolution. A distance of <10 −5 is too small for organismal studies. In contrast, the evolutionary distance between cancer cells and the normal tissue is between 10 −7 and 10 −5 , or ultramicroevolutionary. Cancer evolution analysis is based on the sum of branch lengths (C i , for the i-th case) and requires these branches to evolve in the same direction or converge.
contrast, has, on average, an evolutionary distance of ∼10 −6 or ∼1 bp per Mb of single nucleotide change (68, 77, 136) . We refer to this fine-scale evolution as the ultramicroevolutionary process.
Second, although cancers have extremely short evolutionary distances, the evolution is massively reiterated. Changes are hence summed over many branches in order to discern the evolutionary pattern. The continual reenactment of evolution provides a unique opportunity to address a long-standing issue in evolutionary biology. Does selection drive the evolution along a relatively deterministic pathway, or does evolution follow no particular pattern, with each pathway influenced by numerous contingent factors? Gould (52) invoked the metaphor of rewinding the tape of life's history and asked whether in repeated evolution life forms would end up in the same place as we observe today. He speculated that evolution is contingent and the world would look very different. Others disagreed, suggesting a defined set of patterns (97) .
The debate, in essence, is about whether evolution is a process of adaptive convergence or adaptive divergence. The debate has only rarely been vigorously pursued for the obvious reason that there is generally no easy way to test the hypotheses. It is conceivable that an experimental system with identical starting materials may provide some answers (154) . Tumorigenesis of the same tissue is possibly a natural system with nearly the same starting materials (normal tissue of a human) that are selected to proliferate in similar environments. Independent evolution of tumors from normal tissues is indeed endlessly repeated in large and long-living species. In this regard, species that are far less susceptible to cancer are very interesting as well (1, 98, 131) .
Third, in cancer evolution, the mutation rate itself may be evolving (2, 87, 118, 142) , whereas the mutation rate changes slowly, if at all, in organisms (59, 69, 79) . Furthermore, the partition of nucleotide substitutions into transitions and transversions captures the pattern across many taxa (79), but they vary substantially in different types of cancers (2, 60, 68, 77, 87) . Similarly, chromosomal ploidy change, copy number variation, and epigenetic modification are all common in cancer cells (4, 11, 115, 145, 150) but rare in germ lines. Because genome instability in tumors is frequently observed (31, 57, 150) , whether the instability is necessary for tumorigenesis has been a contentious issue (14, 43, 146) . A high mutation rate can lead to mutational meltdown and population extinction (72, 83) , a theoretical possibility that is difficult to test in nature but could be testable on cancer.
In summary, cancer evolution is sufficiently different from organismal evolution to require modifications of a number of rules but may also provide new perspectives on the general issues of biological evolution. At this moment, the molecular population genetics theories (23, 30, 38, 59, 70, 79, 96, 99, 140, 144) , with the appropriate modifications indicated above, are the best tools to analyze cancer evolution. These theories are robust for various demographic scenarios such as the Fisher-Wright or Moran model. They have also incorporated population size change, spatial structure and overlapping generations, all of which operate differently in tumors than in natural populations. Should future empirical data on tumors suggest unanticipated demographies that defy the existing population genetic models, new theory may be needed. At present, neither the necessary data nor the alternative theory is available.
Finally, all theories generate null predictions based on the knowledge of mutation rate and pattern. For that reason, this review focuses on single nucleotide substitutions. Other types of changes such as copy number variation or epigenetic change, however important we suspect they might be, cannot be modeled adequately before their mutation rates are determined.
DIVERGENT VIEWS ON THE EVOLUTION OF CANCER
What evolutionary principles deduced from the study of natural populations can, or cannot, be applied to cancer evolution? We focus on natural selection, which can be positive (for the beneficial mutations) or negative (against the deleterious ones). Unless specified, selection here denotes positive Darwinian selection. The power of negative selection in cancer evolution has received scant attention but is likely to figure more prominently in the future (10, 90, 91 ) (see Stage I of Cancer Evolution: Tumors Versus Normal Tissues). We shall now review the different approaches to natural selection in cancer biology and evolutionary studies.
Neutralism as the Null Hypothesis
In studies of natural populations, neutral evolution is the null hypothesis (30, 38, 59, 70, 79, 99) . It is assumed that natural selection is not needed to explain the patterns of DNA changes unless the null hypothesis can be rejected. In the cancer evolution literature, natural selection is assumed to be in operation unless proven otherwise (3, 18, 49, 59, 92, 101, 110, 125, 126, 136, 139, 149) . Among the evolutionary forces, including mutation, selection, genetic drift, and migration, positive selection is the only force that may or may not operate in a given system. [However, negative selection against deleterious mutations is pervasive as most nonsynonymous changes, for example, are deleterious in nature (70, 79, 99) ] Neutralism, being a simpler explanation, should be the null hypothesis. It is accepted when the observed pattern of evolution is statistically compatible with a model that requires no (positive) selection. Selection may operate at times, but the overall pattern does not deviate from the neutral prediction. The neutral model therefore permits us to predict the behavior of the system, such as the total amount of genetic diversity. When the neutral prediction is rejected, we may estimate the degree of deviation as a gauge of the strength of selection. Testable hypotheses under a model of selection, in contrast, can be generated only when the mechanism of selection can be precisely defined.
The history of molecular evolution is instructive. Before the introduction of molecular tools to measure evolutionary rate and genetic diversity, it was commonly assumed that most genetic variants in nature have a fitness consequence. The reported high genetic diversity in nature (58, 78) made the conventional view untenable as selection tends to reduce, rather than enhance, genetic diversity. In the past 50 years since the proposal of the neutral theory of molecular evolution (69, 71) (40) , and other tests such as the extended haplotype homozygosity and F ST tests (116, 137, 143, 151) .
Selection Driving Genetic Convergence
Genetic convergence may be the intellectual basis of the TCGA project that searches for the common mutations of cancers (12, 27, 51, 68, 76, 77, 105, 112, 128, 136) . In contrast, the view of genetic divergence is generally held by students of natural populations. When different taxa migrate to the same new habitats, adaptive genic convergence is so rare that each case of molecular convergence has received substantial attention. The adoption of echolocation, the digestion of celluloses, and the colonization of high-altitude plateaus are such examples (42, 107, 153) .
Selection in Relation to Complex Adaptation
As noted in Figure 1 , tumorigenesis is ultramicroevolutionary, with extremely small divergence from the normal tissues. Whether and how complex adaptations such as cellular cooperation (16, 46, 67, 126) could have evolved is intriguing, given the minimal evolutionary distances. It has been suggested that mutations with a large phenotypic effect could be the basis of the large shift in cell behaviors, in the spirit of Richard Goldschmidt's "hopeful monster" (49) . Such large shifts are usually deleterious and cannot be easily fixed in natural populations (75) . They can be observed in domestication thanks to human interventions (19, 94) but are uncommon in natural species (132) . Given that the hypothesis of large effect with few genes is testable [for example, by transgenic procedures (55, 56) ], the absence of such tests should be remedied.
Selection in Growing Populations
Cancer evolution is accompanied by population expansion. However, the means by which selection operates in growing populations are understood very differently in the two fields. In cancer biology, population expansion means excess resources; hence, selection for or against new variants is reduced (18, 101, 110, 126, 139) . Genetic drift is also interpreted as becoming stronger in expanding populations in cancer studies (49) , whereas genetic drift is usually thought to become weaker as the population size gets larger. These interpretations are exactly the opposite of the core understanding of population genetics (38, 59, 70, 79) . It is possible that organismal and cellular populations are fundamentally different but the differences, if indeed true, have not been delineated.
General Comments
The fields of cancer biology and evolutionary biology embrace the subject of cancer evolution with very different perspectives. They even use the same terms for very different concepts. For example, macro-versus microevolution is a delineation of scale in evolutionary biology (see Figure 1) , whereas cancer biology uses them to denote large versus small genetic effects underlying phenotypes (6, 49 in domesticated plants and animals (19, 94) might be considered macroevolutionary. In this review, we adopt the terms used in evolutionary biology, or, more specifically, population genetics, when describing the evolutionary attributes of cancer.
CANCER EVOLUTION IN TWO STAGES
We now examine the empirical data on cancer evolution, which is divided into two stages (see Figure 1 ). Stage I is the evolution of tumors from normal tissues. Here, a tumor is a new population of cells that have become biologically different from the population of normal cells. The following section is about this stage, which is analogous to the molecular evolutionary analysis between species (79, 99) . Stage II is the evolution within tumors. This is the process of population expansion from a single cancerous cell. The section Stage II of Cancer Evolution: Diversification Within Tumors deals with concepts analogous to molecular population genetics (38, 59 ) and focuses on the differentiation among cancerous cells within the same individual. Although the two stages of evolution are separate parts of a continual process, they do have different properties. Indeed, the MacDonald-Kreitman test (89, 93) was developed to exploit the differences between the two stages for the purpose of inferring positive selection. The analytical tools for the two stages are also different.
STAGE I OF CANCER EVOLUTION: TUMORS VERSUS NORMAL TISSUES
The analysis of cancer evolution is predicated on adaptive convergence, which can be in phenotype only or in both phenotype and genotype. We shall very briefly address phenotypic convergence first.
Evolutionary Convergence in Phenotype
Tumorigenesis is a process of phenotypic convergence. After all, this is how pathologists define and stage tumors. Hanahan & Weinberg (57) defined a number of convergent phenotypes that they referred to as cancer hallmarks. These included autonomous growth signaling, evasion of growth suppression, resistance of programmed cell death, avoidance of immune suppression, and acquisition of cell motility as well as other emerging hallmarks.
The quest for signatures of convergence has expanded into defining molecular phenotypes, and the most common examples are biomarkers (8) . Extending the theme, many studies introduced gene expression profiles and other molecular features into cancer typing (5, 62, 65, 85, 95, 112, 114) . All these efforts reflect the underlying assumption that tumorigenesis is a process of evolutionary convergence. Molecular phenotypes are often empirically defined without a prior expectation. An interesting exception may be the convergence in the expression pattern that regresses back to the embryonic stem cells (9, 24, 109) . This view takes a further step beyond the dedifferentiation hypothesis (80, 141) , under which cancer cells regress back to the tissue stem cells.
Evolutionary Convergence in Genotype
To discuss genotypic convergence, we need to have an overview of The Cancer Genome Atlas (TCGA) that has been motivated by the view of adaptive genic convergence in tumor evolution. TCGA, in collaboration with the International Cancer Genome Consortium (ICGC; htttp://icgc.org), aimed to discover the shared genetic bases by sequencing a large number of cancer genomes. Since then, the consortium has generated comprehensive sequencing data on somatic mutations, gene expressions, and epigenetic modifications from ∼15,000 matched tumor and normal tissues for 49 different cancer types. At present, 1,374,866 single nucleotide variations (SNVs) in coding regions have been reported. These SNVs and other changes can be found in the ICGC data portal (https://dcc.icgc.org/). Across all cases, the median number of coding region mutations per cancer case is approximately 50, although a few cases may be more than 20 times higher.
The TCGA-ICGC data have been comprehensively analyzed from the cancer biology perspective (12, 27, 51, 68, 76, 77, 112, 128, 136) . Overall, there are two salient results from the survey. First, there is only a modest overlap in genes that have mutated among cases of the same type. The overlap is even less across different cancer types. Hence, adaptive convergence is uncommon even when driven by similar selective forces (see below for details). Second, a most surprising result is the apparent lack of selection signals in the TCGA data. The intensity of selection in each cancer case can be expressed as the K a /K s ratio (59, 79) , where K a is the number of nonsynonymous changes and K s is the number of synonymous changes per nucleotide site, respectively. In almost all surveys of cancer evolution, K a /K s is approximately 1 across cancer types (104) . Given that a K a /K s = 1 is the signature of neutral evolution (59, 79) , it would appear that most tumors have been evolving neutrally.
In the following two sections, we separately review the two sets of results (lack of convergence and lack of overall selection). Although they both pertain to selection, they can be either strongly correlated or completely uncorrelated. For example, all cancer cases may experience strong selective pressures but do not converge genetically. Alternatively, different cancer cases may be driven by weak selection, which may nevertheless converge. Convergence and selective intensity are distinct phenomena.
Low genotypic convergence. The original aim of finding common mutations that would identify a full set of cancer driver genes has turned out to be unattainable. For example, in the analysis by Kandoth et al. (68) , only two genes are mutated in more than 10% of all cancer cases (TP53 at 42.0% and PIK3CA at 17.8%). Other reports present similar patterns (see 77, 128, 136) . Although passengers are not expected to be commonly shared among tumors, a substantial sharing of driver mutations among tumors was the expectation. The fact that one can often find two tumors of the same type that share no mutation in the same genes underscores the disappointingly low convergence among tumors.
Common occurrences of mutations are somewhat more likely for individual types of cancer. For example, the VHL gene is mutated in 52.3% of kidney cancers but is only mutated in 6.9% of cases across 12 cancer types. This is true for a few other genes, such as APC (82% in colorectal cancer versus 7% across multiple cancer types), ARID1A (28% and 30% in bladder and uterine cancers versus 5% in general), FLT3 (27% in glioblastoma and 3% in general), and CTNNB1 (28% in uterine cancer and 3% in general). Higher genetic convergence is expected in the same tissue environment. Nevertheless, the number of common cancer drivers is rather modest even for the same cancer type (see figure 4 of Reference 68, for example).
In these analyses, common driver mutations are shown as the percentage of occurrences among cancer cases. However, longer genes are proportionately more likely to be represented and cases with more observed mutations have correspondingly more genes associated with the tumors. All these factors need to be corrected. For the same reason, genetic convergence at the pathway or network level (5, 27, 62, 112) greatly exaggerates the commonality of mutations because a pathway or network is equivalent to a supergene of enormous length.
In algebraic terms, the percentage of a mutated gene in cancer samples is P(U|D), which is the probability of a gene having a mutation (U) in the sample, conditional on the sample being in the diseased state (D). The cancer-driving potential can be better represented by
where P(U) is the probability of having the mutation in the gene in the control population. Thus, λ is the enrichment index, or the relative likelihood of having the mutation, given the disease. Cancer driver genes are identified when P(U|D) is statistically larger than P(U), i.e., when λ > 1 (77), although the actual λ has rarely been given. Under specific circumstances, λ can also be rearranged as P(D|U)/P(D) with the interpretation of the risk of having the disease with the mutation, relative to the probability of having the disease with or without the mutation. In this review, we focus on the evolutionary rates of the cancer genomes by analyzing K a /K s for each gene. K a is equivalent to P(U|D) and K s is equivalent to P(U), the latter being the expected occurrences of neutral mutations. K a /K s is hence a measure of λ.
Before we discuss the evolutionary rate, which is central to the identification of cancer driver genes, we should also note that the quest for convergence signals has motivated many additional measurements that change P(U|D) and P(U) in ways that might increase λ. The measurements vary greatly, ranging from expression data and structural genomics to network analyses. Structural genomic information such as protein domain, post-translational modifications, protein pockets, and protein-ligand binding sites has been integrated into the algorithms (25, 111, 138, 152) . Network-based analyses have also been extensively applied to decipher the tumorigenic consequence of somatic mutations. These include pathways, gene interaction networks, and mRNA expression networks that may be sensitive to the effects of rare somatic mutations (7, 133, 134) . An intricate example is TieDIE (tied diffusion through interacting events) (108), which incorporates genomic and transcriptomic data into networks of protein-protein interactions and computationally predicts TF-to-target connections.
Our objective is not to evaluate the merits of each individual measurement (pathway, network, expression, etc.). Instead, we aim to identify the common features of driver genes that appear on most lists of putative driver genes. A low consensus rate (31.0%) in somatic mutation calling has been noted (39) and, in the more extreme cases, two lists of cancer driver genes do not overlap at all (57) . With the TCGA data of somatic single nucleotide mutations, candidate driver lists overlap much more extensively, and the overlap is mainly a function of the evolutionary rate, shown below. We compare the three comprehensive analyses that identify 127, 140, and 180 cancer driver genes (68, 77, 136) , respectively. In total, there are 257 genes, among which 59 genes appear on all three lists.
We ask what features delineate the common subset. Figure 2 shows the proportion of genes that are included in one, two, or three lists as a function of K a /K s . For genes that are included in all three lists, the K a /K s ratios tend to be high ( Figure 2 , blue bars; 72% and 6.8% for K a /K s >5 and <1, respectively), whereas genes that appear in only one list tend to have lower K a /K s ratios (Figure 2, green bars) . In short, the consensus candidate driver genes are those that evolve fast. The other measures such as gene expression level tend to introduce slower evolving genes that are not agreed upon by different studies. There are genes with low K a /K s ratios that appear in all lists, such as VHL and APC; these genes in fact have high K a /K s ratios in specific cancer types. Had we considered specific cancer types, Figure 2 would have shown that almost all consensus driver genes have high K a /K s ratios in some or all cancer types.
Because the number of cancer drivers that have been confidently predicted and shared by most gene lists is modest, there may be a larger collection of cancer driver genes that have eluded detection. How many are there and what are they? By analyzing the selective pressure on mutated genes in the next section, we hope to answer some of these questions. Number of data sets
Figure 2
Proportion of cancer driver genes identified by one, two, or all three published analyses (indicated by green, pink, and blue bars, respectively). The distributions show that the consensus calling of cancer driver genes is determined mainly by the evolutionary rates of genes. Table 1 , the K a /K s ratio is scattered around 1 with a mean of 1.00 (see Table 1 ). Such parity is often strong evidence for neutral evolution, as seen in pseudogenes and other nonfunctional portions of the genomes such as intergenic sequences (59, 79) . Selection apparently does not operate on these changes. In comparison, the K a /K s ratio for coding genes in the human-macaque comparison is 0.21, and in the human-mouse comparison it is 0.12 (see Table 1 ). Therefore, in natural populations, 80-90% of nonsynonymous mutations are eliminated by natural selection, whereas genic evolution in tumors appears to be neutral on account of the K a /K s ratios.
In conclusion, K a /K s ∼ 1 in Stage I of cancer evolution is an interesting surprise. Although neutrality has been increasingly suggested for the evolution of intratumor diversity in Stage II (81, 121, 123, 147) , it is generally believed that selection should be the main driving force in Stage I. An analogy is that the DNA diversity within human populations could be neutral but the divergence between human and chimpanzee should be selectively driven (79) .
The counter-action of positive versus negative selection: A gene-by-gene analysis. In this long section, we shall first cover the theory before applying the theory to the data. A review of the population genetics theory. Strictly speaking, K a /K s = 1 does not mean the absence of selection. It only means that the effect of positive selection in accelerating evolution is exactly canceled out by the effect of negative selection that slows it down. Because it seems too much a coincidence that the positive and negative effects could be so close in strength, neutrality is generally the more plausible explanation. However, in tumorigenesis, many genes are known to bear a strong signature of positive selection (12, 27, 51, 68, 76, 77, 112, 128, 136) ; hence, the large impact on the K a /K s ratio by even a tiny fraction of advantageous mutations needs be quantified.
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For that reason, neither should we ignore the possibility of negative selection operating on many other genes.
Wu et al.
As all living systems are driven by both positive and negative selection (22, 38, 59, 79) , there should also be two types of selectively-driven genes in cancer evolution: positive drivers and negative drivers. The former are genes whose mutations, on average, confer a proliferative advantage and speed up the evolution, whereas the latter are deleterious mutations that slow it down. The term "negative drivers" may help to raise the awareness of deleterious mutations. The relative abundance and selective strength of positive and negative drivers are crucial for understanding tumorigenesis.
Let the proportion of nonsynonymous sites under positive and negative selection be p and q, respectively. The rest, 1 − p − q, is neutral. Synonymous sites are assumed to be neutral. According to the classical theory (30, 38, 59, 70) , the probability of fixation for a beneficial mutant with a fitness advantage of s is 2s. Deleterious mutations are assumed to have a very small probability (ε∼ 0) of becoming fixed. The neutral mutation is fixed with the probability of (1/N e ). We should note that the probability of fixation given here is general and depends little on the specific models. For example, the fixation probability of 2s can be obtained by the branching process as well (see 30) . Thus, the standard theory would show
where N e is the effective size of the cell population. Let the observed K a /K s be R, then
In most natural species, R < 0.3 and q > 0.7 (79) . Negative selection thus overwhelms positive selection, making the analysis of positive selection difficult. In contrast, R ∼ 1 in cancer evolution, suggesting nearly equal impacts by positive and negative selection. (Note that R ∼ 1 does not automatically indicate neutrality. A system with p = 0.01, q = 0.99, 2N e s = 100 and no neutral mutations would also yield R ∼ 1.) The relationship between p and q when R = 1 can be thus delineated
Using Equation 2, q p unless N e s is close to 1. [When N e s = 1, the selective advantage vanishes because it would be the same as the drift effect (1/N e .)] If 2N e s = 5, negative drivers are four times as numerous as positive drivers (q = 4p). Note that 2N e s = 5 is very weak selection. For example, in human populations with N e ∼ 10 4 (59), the selective advantage of 2N e s = 5 would be merely s = 0.00025. Clearly, to maintain an overall K a /K s ∼ 1, every positive driver needs to be balanced by many times more negative drivers. As 2N e s increases, the disparity also increases. From the data, we can obtain the approximate N e s value for each gene (averaged over all sites of the genes). The fixation rate of nonsynonymous mutation for a gene is K a = 2N e su and K s = N e u(1/N e ) = u. Hence,
Application of the theory to the The Cancer Genome Atlas data. 
Figure 3
Distributions of the evolutionary rate (K a /K s ) of individual genes in cancer versus organismal evolution. Although the genome-wide average of K a /K s is very close to 1, the K a /K s ratio for individual genes often deviates from 1. Computer simulations assuming all genes with K a /K s = 1 show 5.3% and 0.2% of genes to have K a /K s < 0.5 or >2, respectively. In contrast, the observations show much higher percentages of genes in these two categories. The deviations are greater for individual cancer types [∼26% and ∼10% for HNSC (head-neck squamous cell carcinoma) and BLCA (urothelial bladder carcinoma)] than for the pan-cancer pattern (∼17% and ∼5%). The pan-cancer distribution is based on many more samples and is considered more accurate. For a comparison, the distribution of K a /K s between human and macaque is strongly skewed, with 86.1% of the K a /K s ratio being <0.5. Table 1 presents all genes with 2N e s > 8 (strongly beneficial mutations as defined in Figure 3 ) either across all cancer types or in at least one of the two tissue types. It is striking that the second half of Table 1 consists entirely of genes that are selected strongly in only one cancer type. Figure 3 shows the distribution of K a /K s ( = 2N e s) for individual genes during tumorigenesis. For a comparison, we also present the K a /K s distribution between human and the macaque monkey, which shows very few genes with K a /K s > 1. The prospect of detecting positive selection in cancer evolution is much better (see Figure 3) , which is informative in several ways.
First, although the K a /K s distributions in cancers yield a mean ratio of ∼1, we see excesses on the positive and negative sides in comparison with the simulated distribution that assumes all genes to have the same K a /K s ratio. The existence of beneficial mutations has been amply confirmed by previous TCGA analyses (12, 27, 51, 68, 76, 112, 128, 136) and the existence of deleterious mutations is a logical corollary, given that the mean K a /K s is ∼ 1. We will explore the genes under negative selection in a follow-up study (in preparation).
Second
are, on average, deleterious), between 0.5 and 2 as effectively neutral, and >2 as advantageous. Given the short evolutionary distance, a gene observed to have K a /K s = 2 may not be statistically different from K a /K s = 1.
Genes with K a /K s > 8 are considered strongly advantageous and only approximately 0.1% of genes are in this category. Although 5-10% of the genes are weakly but positively driven, 17-28% of genes are at least equally strongly driven, but in the negative direction. In the cancer evolution literature, little attention has been paid to the effect of deleterious mutations (10, 90, 91) , which, given their number, could be a drag on the evolution of tumors.
Third, the K a /K s distribution appears broader in specific cancer types than in the pan-cancer analysis. A simple interpretation is that there are more genes under selection, in both the positive and negative directions, in individual tissues than in the pan-cancer data. As many mutations are advantageous or deleterious only in some particular tissue environments, some previous studies (104), using different analyses, have hinted at such properties. We suspect that the tighter distribution in pan-cancer data with more cases falling in the middle of the distribution may be due to their much larger sample sizes. A preliminary study correcting for the sample size difference suggests that the average intensity of selection on each individual type may indeed be smaller than portrayed (H.-Y. Wang & C.-I.Wu, in preparation).
In summary, there are a large number of weak driver genes (5% of all genes across cancer types and ∼10% for specific types) that could account for the missing drivers, as noted before (136) . There are in addition roughly three times as many negative drivers. In the absence of recombination, positive and negative selection would mutually interfere.
The causes and consequences of weak selection in cancer evolution. The causes of weak selection could be due to the very small N e 's in tumors. A consequence of weak selection is the low level of convergence, which requires strong selection.
Causes of weak selection. The role of selection in cancer evolution appears to be much weaker than necessary to drive genotypic convergence. Several studies have also suggested weak selection by attempting to estimate the selective intensity (s) directly (15, 121, 135) . From the literature, we obtain estimates of 2N e s, which governs the pattern of evolution. When multiplied by 2N e , the selective effect is weak in cancer for several reasons. First, the extremely short evolutionary distance in each tumor means that even the strongest mutations may not have a chance to emerge. Second, 2N e s is small because N e may be small, whereas s may not be. Cairns ' (20) suggestion of the compartmentalization of stem cell populations is nature's way of reducing N e . (Note that N e here is in reference to the effect of selection.) Ling et al. (81) also suggested that the low cell motility in solid tumors greatly reduces the efficacy of selection. Third, mutations emerge as heterozygotes in which mutations need to be semidominant to have a fitness effect. Fourth, the preponderance of deleterious mutations would offset whatever growth advantages cells may have previously acquired.
Consequences of weak selection. The low efficacy of selection may be an important reason for the observed low convergence in cancer genotypes. Strict convergence dictates that, in each step of cancer evolution, a very small subset of mutations would have an overwhelming selective advantage. Consequently, they are almost always the ones that are fixed. Indeed, the deterministic model of Jones et al. (66) step-by-step changes on APC, CDC4, Kras, PIK3A, and p53 (41, 101) . This sequential model has been influential since its proposal (103) . How much selective advantage (2N e s) does a mutation need to confer a result in convergence? According to the TCGA data, the neutral (i.e., synonymous) substitution number is roughly 3 × 10 −6 per site on average. An average sized gene with 450 codons has approximately 1,000 nonsynonymous sites. Therefore, its neutral mutations should be present in 0.3% (=3 × 10 −6 × 1,000) of all cancer cases. A nonsynonymous mutation with a selective advantage must be more common than the neutral ones. Given an enrichment of λ [= P (U|D)/P (U) ∼ K a /K s ], the mutation is expected to be present in 0.3% of λ cases. Even with K a /K s = 10, such mutations should still be present in only 3% of cancer cases, and there are only 10 genes with K a /K s > 10 in the pan-cancer analysis ( Table 1) . The P53 gene, with a K a /K s value of 80-150, is a stark standout in the genome. Figure 3 and Table 1 show 40 or so genes that contribute to the modest genotypic convergence in the TCGA data (12, 27, 51, 68, 76, 112, 128, 136) . Beneath these genes is a broad class of genes with weakly advantageous mutations (2 < K a /K s < 8). Such weak advantages could be easily offset by the many deleterious mutations in the genome (genes with K a /K s < 0.5).
Additional notes.
Little is known about the ecology underlying the selection. For example, what ecological factors of the kidney, but no other tissues, make VHL strongly selected? The same applies to Kras in the pancreas and APC in the colon (13, 117, 120) ? We may also ask whether the same organs in different mammals impose different selective pressures on the same set of genes. For example, are APC mutations as common in dog's colorectal cancer as they are in humans? Although the prevalence of different cancer types between human and dog have provided some hints, the cross-species cancer genomics may offer new insights into cancer evolution. The low incidences of cancers in mole rat (131) , elephant (1, 124) , and whale (98) have shown the promise of broader investigations.
STAGE II OF CANCER EVOLUTION: DIVERSIFICATION WITHIN TUMORS
We now ask how strongly natural selection operates in Stage II of cancer evolution (Figure 1 ) and how much genetic diversity accumulates in the process. In any population of organisms or cells, mutations occur during DNA replication. Through time, individual DNA copies accumulate differences, resulting in genetic diversity. This diversity, usually measured by DNA sequencing, provides information about the demography of the population, including growth mode, population subdivision, migration, etc. If, and only if, the observed diversity deviates from the expected value that is based on the given demography need natural selection be invoked.
The possible operation of natural selection in tumors is also important for clinical reasons. First, clones that are positively selected may be of particular clinical concern. Second, if selection is not operative, the intratumor diversity would generally be expected to be larger. Note that selection tends to reduce diversity, with new advantageous mutations driving out existing variants and deleterious mutations being eliminated by the wild-type clones. When the neutral diversity becomes sufficiently large, the probability that the standing genetic variation might confer drug resistant is correspondingly large.
Evidence for Natural Selection Driving Intratumor Diversity
The first empirical measure of within-tumor diversity is that of Shibata (119) , who studied microsatellite variations. Following that seminal study, other measures such as IgA diversity, DNA copy number variation, loss of heterozygosity (LOH), chromosome ploidy differences, and methylation patterns (17, 21, 54) have all been used to confirm clonal diversification within tumors. In recent years, whole-genome or whole-exome sequencing has become the method of choice (31, 48, 130) . In this section, we evaluate the approaches that conclude the role of natural selection driving within-tumor diversity.
Sharing of intratumor variants. Gerlinger et al. (48, 50) presented the common occurrences of SETD2 mutations in renal cell carcinomas as a signal of convergent selection within tumors. In light of the modest success in finding convergence signals in the TCGA data (68, 76, 136) , a statistical assessment of the suggested enrichment is necessary (see Stage I of Cancer Evolution: Tumors Versus Normal Tissues), especially when common independent mutations within the same tumor are quite rare in such studies. Furthermore, Ling et al. (81) estimated the number of intratumor coding mutations to be in the hundreds of millions, mostly in low frequencies. Hence, sharing of intratumor variants that are not in high frequency could be noisy background occurrences.
Genetic diversity driving tumor progression. The level of intratumor genetic diversity has been shown to be correlated with cancer progression and mortality (3, 86, 88, 106) . It has hence been suggested that the higher intratumor diversity was driving aggressive tumor growth. Nevertheless, it seems no less likely that aggressive clones are dividing more frequently and, hence, accrue more diversity as a consequence. This is particularly true when the diversity measure is based on nonfunctional variants such as microsatellites. In other words, the higher genetic diversity may be the consequence, rather than the cause, of aggressive tumor growth.
Relapse after drug treatment. Higher genetic diversity may indeed predispose faster cancer evolution if the environment changes drastically. Many reports have shown that resistant clones usually pre-exist in the original tumors but in very low frequencies (26, 32, 84, 100, 113) . That neutral variants can become selectively different in changing environments has been demonstrated in Escherichia coli and yeast, a phenomenon referred to as the Dykhuizen-Hartl effect (35, 70) . Because neutral diversity is characterized by a very large number of low-frequency variants (81), the emergence of low-frequency drug-resistant mutations is not unexpected.
Functional tests by xenografting.
A functional approach to testing fitness differences among subclones of the same tumor is to compare their growth rate in vitro or as xenografts (24, 36, 73) . Although the observations have been suggested to reveal fitness differences between subclones of the same tumor, they in fact pertain to the continual evolution of these subclones in new environments, rather than in the original tumors.
In short, the inferences of selection driving intratumor diversity often pertain to the consequences of environmental changes on the diversity, rather than selection during tumor growth. Direct tests are reviewed next.
Evidence Supporting the Neutrality of Within-Tumor Diversity
A direct approach to assessing the effect of selection on intratumor diversity is to compare the sizes of the observed clones with the neutral expectation. The expected neutral pattern in stationary populations can be obtained from both the infinite-allele or infinite-site models of population genetics (30, 38, 59, 70, 79, 99) . The models have been extended to exponentially growing populations in which the clone size distributions can be obtained mathematically (33, 34, 74, 148 carried out (81, 123, 129, 147) . These theories are often built on the coalescence framework of population genetics (140) . Only a handful of studies have been carried out to explicitly compare the observed intratumor diversity with the theoretical predictions. These studies look for unexpectedly large clones as an indication of positive selection, and all concluded that neutral evolution is an adequate explanation for the observed intratumor diversity (81, 123, 129, 147) .
It should nevertheless be noted that the failure to reject a null hypothesis might be due to the low power of the test because of, for example, insufficient sampling. Indeed, few cancer evolution studies sequenced more than a small number of samples from the same cell population. Although several studies have genotyped a few more samples, the power and resolution of cancer evolution studies are quite low in comparison with studies of natural populations, which usually sequence tens or hundreds of samples. Furthermore, there is an important distinction between solid tumors and leukemia. A strong spatial structure in solid tumors permits local sampling of cells belonging to a genealogical clone. Bulk sequencing of local samples can thus substitute for single cell sequencing, which remains impractical at present. Leukemia samples do not contain spatial information for genealogical analyses.
Ling et al. (81) sequenced 23 samples, and genotyped 286 in total, from a plane in the middle of a 3.5-cm liver tumor. They showed that the 35 mutation clones follow the predicted size distribution. The power of the neutrality test is demonstrated because a small number of unexpectedly large clones should have been able to reject the neutral model. The issue of power may be relevant to the study of Williams et al. (147) , who used the mutations that are locally polymorphic but globally rare for the test against neutrality. Wang et al. (141) suggested that mutations with globally low frequencies in the whole tumor offer little power to distinguish between selection and neutrality.
Tao et al. (129, 130 ) used a qualitative test by comparing descendant clones with their parents in 12 cases of hepatocellular carcinoma with multiple tumors in the same liver. The younger clones, having additional mutations, should have started proliferating later and are expected to be smaller under the neutral model. They found that clonal comparisons within a single tumor invariably uphold the neutral model. Most interesting of all, when the same test is used on different tumors of the same organ of the same patient, the neutral model is rejected in all seven informative cases.
Implications of Neutral Diversity within Tumors
The amount of within-population diversity should generally be larger under neutrality than under selection (38, 40, 45, 59, 63, 79, 89, 127, 151) . If diversity-enhancing selection is suspected to be operative (64) , it needs to be defined with clearly formulated predictions. Under neutrality, Ling et al. (81) suggested that under a model with the average mutation rate, the number of coding mutations in a 3.5-cM liver tumor is expected to be greater than 100 million. The level of intratumor diversity is mainly a function of the number of cells in the tumor.
Although the large diversity may seem discouraging, it is important to note that the bulk of mutations exist in fewer than 100 cells. Many therapeutic strategies (47, 113, 122) aiming at preventing the spread of resistance work particularly well if the resistance mutations are rare in the cell populations. The data on relapses appear to support that position. Hence, the evolutionary approaches to cancer can be clinically relevant.
CONCLUSIONS: EVOLUTIONARY AND MEDICAL IMPLICATIONS
This review explores the means by which evolutionary forces operate across scales, from macro to micro to the ultramicro cancer evolution. Because the action of natural selection can only be inferred, its central role in organismal evolution has been challenged twice in the past century, the first time by the mutationist school and the second time by neutralism (99) . Cautions against excessive invocation of natural selection have also been raised many times (53) .
In this review, using standard population genetics theory on published results, we find that selection operates with lower efficacy in cancer evolution than in natural populations. This is true in both Stage I and II (see Figure 1) . Selection efficacy is a function of N e s, and N e may be rather small in tumorigenesis. This review also finds extensive negative selection against nonsynonymous mutations, which greatly outnumber those under positive selection. Given the absence of recombination, the interference of positive and negative selection (the Hill-Robertson effect; 23, 61) renders selection rather ineffective. This mutual interference is particularly strong when the mutation rate is large.
A caveat is that this review only addresses selection on single nucleotide substitutions. Different types of genetic variants may be under different selective pressures. Hence, copy number variation (CNV) or epigenetic changes could be driven by selection, as is often suggested (26, 32, 84, 100, 113) . The efficacy (or lack of ) of selection on such variants, however, remains unclear. For example, mutational hot spots for CNVs are not uncommon, and their occurrences in tumors could be due to mutation, selection, or both.
The conclusions of this review have both medical and evolutionary implications. First, the overall weak selection has not led to the strong genotypic convergence, as had been hoped for. Nevertheless, the convergence in phenotypes is manifested in the many cancer hallmarks (57) . Whether cancer therapy should target such convergent phenotypes, instead of genotypes, is an interesting question. Targeting the genotype implies a therapy that is exquisitely tuned to each individual. Although we have seen limited successes using this approach, making it a widespread and common approach is an uncertain prospect. Phenotypic convergence, old fashioned as it may be, remains a viable therapeutic option. Second, although evolutionary principles help us understand tumorigenesis, the reverse is also true. There are many long-standing, seemingly unresolvable questions in evolutionary biology that may find answers in tumorigenesis. The questions of evolutionary convergence (52) , mutational meltdown (72, 83) , and the origin of multicellularity are intriguing examples.
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